These findings are in agreement with the recommendations from the cIMPACT-NOW consortium, which suggests that EGFR amplification and combined chr7 gain and chr10 loss as well as TERT promoter mutation can be used to diagnose the IDH WT grade II/III gliomas that are likely to follow a more aggressive clinical disease course. Here, EGFR is linked to central nervous system cancer.